The effect of prior exposure to imatinib on transplant-related mortality

Haematologica

Volumn 91, Issue 4, 2006, Pages 452-459

  Deininger, Michael ^a   Schleuning, Michael ^b   Greinix, Hilde ^c   Sayer, Herbert Gottfried ^d   Fischer, Thomas ^e   Martinez, Jesus ^f   Maziarz, Richard ^a   Olavarria, Eduardo ^g   Verdonck, Leo ^h   Schaefer, Kerstin ⁱ   Boqué, Conxa ^j   Faber, Edgar ^k   Nagler, Arnon ^l   Pogliani, Enrico ^m   Russell, Nigel ⁿ   Volin, Liisa ^o   Schanz, Urs ^p   Doelken, Gottfried ^q   Kiehl, Michael ^r   Fauser, Axel ^r   Druker, Brian ^a   Sureda, Anna ^s   Iacobelli, Simona ^t   Brand, Ronald ^t   Krahl, Rainer ^u   Lange, Thoralf ^u   Hochhaus, Andreas ^v   Gratwohl, Alois ^w   Kolb, Hans ^x   Niederwieser, Dietger ^u   more..

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HAMMERSMITH HOSPITAL   (United Kingdom)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ KLINIKUM NÜRNBERG   (Germany)

^j CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^k UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^l HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^m SAN GERARDO HOSPITAL   (Italy)

ⁿ NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^o HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^p UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^q UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^r Klinik fuer Knochenmarktransplantation und Haematologie/Onkologie   (Germany)

^s HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^t EBMT Department of Medical Statistics   (Netherlands)

^u UNIVERSITY OF LEIPZIG   (Germany)

^v UNIVERSITY OF HEIDELBERG   (Germany)

^w UNIVERSITY HOSPITAL BASEL   (Switzerland)

^x LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

more..

Author keywords

B cell chronic lymphoproliferative disorders; Biclonality; FISH; Immunophenotype; Intraclonal evolution

Indexed keywords

IMATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BLAST CELL CRISIS; CANCER GROWTH; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; STATISTICAL ANALYSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MORTALITY; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33646013280     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-53.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
3. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
4. Lange T, Niederwieser DW, Deininger MW. Residual disease in chronic myeloid leukemia after induction of molecular remission. N Engl J Med 2003; 349:1483-4.
5. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004;104:2204-5.
6. Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004;28 Suppl 1:S71-S73.
7. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmarm OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
8. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37.
9. Giles F, Kantarjian H, Wassmann B, Cortes J, O'Brien S, Tanaka C, et al. A phase I/II study of AMN107, a novel aminopyrimidine Inhibitor or Bcr-Abl, on a continuous daily dosing schedule in adult patients (pts) with Imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph+) acute lymphocytic leukemia (ALL). Blood 2004;104 [abstract 10a].
10. Sawyers C, Shah M, Kantarjian H, Donato NJ, Nicoll J, Bai S, et al. Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: Results from a phase I dose escalation study. Blood 2004;[abstract 1044a].
11. Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995; 85:2632-8.
12. Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J, Urbano-Ispizua A. Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002; 100:2374-86.
13. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975;292:895-902.
14. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-400.
15. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and post-grafting immunosuppression with cyclosporine and mycophenolate mofetil (MNF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101:1620-9.
16. Schmid C, Weisser M, Ledderose G, Stotzer O, Schleuning M, Kolb HJ. Dose-reduced conditioning before allogeneic stem cell transplantation: principles, clinical protocols and preliminary results. Dtsch Med Wochenschr 2002;127:2186-92.
17. Beelen DW, Elmaagacli AH, Schaefer UW. The adverse influence of pretransplant interferon-α (IFN-α) on transplant outcome after marrow transplantation for chronic phrase chronic myelogenous leukemia increases with the duration of IFN-alpha exposure. Blood 1999; 93:1779-10.
18. Hehlmann R, Hochhaus A, Kolb HJ, Hasford J, Gratwohl A, Heimpel H, et al. Interferon-α before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999;94:3668-77.
19. Loberiza FR, Bolwell BJ, LeMaistre CF, Litzow MR, Marks D, Waller EK, et al. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood 2001;98:3205-11.
20. Visani G, Rosti G, Bandini G, Tosi P, Isidori A, Malagola M, et al. Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. Br J Haematol 2000;109:722-8.
21. Shimoni A, Kroger N, Zander AR, Rowe JM, Hardan I, Avigdor A, et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003;17:290-7.
22. Wassmann B, Pfeifer H, Scheuring U, Klein SA, Gokbuget N, Binckebanck A, et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia 2002;16:2358-65.
23. Zander A, Zabelina T, Renges H, Schieder H, Kratochwille A, Fehse N, et al. Pretreatment with Glivec increases transplant-related mortality after allogeneic transplant. Blood 2003;102 [abstract 468a].
24. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005;105:2473-9.
25. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104:1094-9.